Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117351 · ClinicalTrials.gov registry record · Phase 2
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00117351: Clinical Trial Phase 2 study, sponsored by Millennium Pharmaceuticals.
NCT00117351 is a Phase 2 study that was terminated before completion, run by Millennium Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00117351, a Phase 2 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
This study will evaluate the safety and efficacy of VELCADE in patients with previously treated stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features.
Interventions
- DRUG VELCADE
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-04 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Why NCT00117351 stopped before completion
NCT00117351 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which VELCADE is the first listed.
NCT00117351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00117351 about?
NCT00117351 is a clinical study titled "VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features". This study will evaluate the safety and efficacy of VELCADE in patients with previously treated stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features.
What is the current status of trial NCT00117351?
This trial is currently terminated. It is a Phase 2 study. The study started on 2005-04. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00117351?
The interventions under investigation include: VELCADE (DRUG).
Who is sponsoring clinical trial NCT00117351?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia